University of Pennsylvania to Join First-of-Its-Kind Research Collaboration to Fight Cancer with New Immunotherapies The University of Pennsylvania has joined an unprecedented cancer research effort, the Parker Institute for Cancer Immunotherapy, which unites six of the nation’s top medical schools and cancer centers around a shared aim of accelerating breakthrough immunotherapy research that will turn more cancers into a curable disease. The venture is backed by a $250 million gift from the Parker Foundation, making it the largest single contribution ever made to the field of immunotherapy. [University of Pennsylvania] Press Release UCLA Joins Collaboration to Advance Cancer Immunotherapy Research UCLA has joined forces with five of the nation’s other leading cancer centers and The Parker Institute for Cancer Immunotherapy to maximize the potential of cancer immunotherapy research. [UCLA] Press Release UAB Awarded $19.5 Million Grant for New Xenotransplantation Program The University of Alabama at Birmingham Comprehensive Transplant Institute has been awarded a five-year, $19.5 million grant from biotechnology magnate United Therapeutics Corporation to launch a pioneering UAB Xenotransplantation Program that both groups hope will lead to genetically modified kidney transplants from pig models to humans by 2021. [University of Alabama at Birmingham] Press Release Profusa Awarded $1.75M NIH Grant to Further Develop Tissue-Integrated Biosensors for Continuous Oxygen Monitoring in PAD Patients Profusa, Inc. announced that the National Institutes of Health (NIH) has awarded it a $1.75 million grant under the Small Business Innovation Research program. The funding will support fast-tracked Phase I and Phase II studies of the company’s Lumee™ tissue-integrated biosensors for continuous monitoring of oxygen toward improving the clinical outcomes of patients suffering from peripheral artery disease. [Profusa, Inc.] Press Release Therapeutic Solutions International’s Subsidiary MolecuVax, Inc. to Initiate Cancer Immunotherapy Clinical Trial Aimed at Eradicating Cancer Stem Cells Using MVAX-001 Therapeutic Solutions International, Inc. announced the signing of an agreement between its subsidiary, MolecuVax, Inc., and the Pan Am Cancer Treatment Center covering production and clinical implementation of a novel cancer immunotherapy based around MVAX’s proprietary Brother of the Regulator of Imprinted Sites peptide/exosome technology. [Therapeutic Solutions International, Inc.] Press Release Kadimastem Is Granted a Patent in Japan for Diabetes Treatment Kadimastem announced it was granted a patent from the Japanese Patent Office for its technology in the field of diabetes treatment. The patent is for a method of producing insulin-secreting cells from stem cells, and it is likely to constitute the foundation for the company’s products in the field of stem-cell based treatment of diabetes. [Kadimastem] Press Release Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent Oramed Pharmaceuticals Inc. announced that the U.S. Patent and Trademark Office has issued a Patent Term Adjustment extending the patent term by 18 months for its patent No. 9,259,456, titled, “Methods and Compositions for Oral Administration of Proteins”. The patent addresses Oramed’s platform technology which underlies its products, including ORMD-0801, an orally ingestible insulin capsule. [Oramed Pharmaceuticals Inc. (PR Newswire Association LLC.)] Press Release Tobira Therapeutics and Dong-A ST Enter into License Agreements for Evogliptin and Cenicriviroc Tobira Therapeutics, Inc. and Dong-A ST Co., Ltd. announced that the companies have entered into two separate licensing agreements. Tobira has acquired exclusive rights to develop and market evogliptin in combination with cenicriviroc and as a single agent in the United States, Canada, Europe and Australia for all therapeutic indications. Dong-A has received an exclusive license to develop and market CVC, as both a single agent and in combination with evogliptin in the Republic of Korea for all therapeutic indications. [Tobira Therapeutics, Inc.] Press Release Oncternal Therapeutics Awarded Exclusive Worldwide License to ROR1 Antibody and Related Programs from UC San Diego Oncternal Therapeutics, Inc. announced that it has received an exclusive worldwide license to develop and commercialize antibodies and antibody-related binding agents recognizing receptor-tyrosine kinase-like orphan receptor 1 (ROR1) from University of California San Diego. [Oncternal Therapeutics, Inc. (PR Newswire Association LLC.)] Press Release CeQur Initiates Significant Facility Expansion in Marlborough CeQur® announced that the company is doubling the size of its Marlborough facilities in preparation for the launch of PAQ®, the company’s simple, three-day insulin infusion device. [CeQur®] Press Release |